Qyuns Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	806.96	158.79	-	-	-
Other Revenue	-	-	-	9.66	21.35
Revenue	806.96	158.79	-	9.66	21.35
Revenue Growth (YoY)	408.18%	-	-	-54.74%	-
Cost of Revenue	92.55	66.6	-	-	-
Gross Profit	714.41	92.19	-	9.66	21.35
Selling, General & Admin	130.4	116.85	164.59	76.6	48.8
Research & Development	253.17	334.28	364.4	257.21	151.89
Other Operating Expenses	-1.3	-16.66	-14.74	-	-
Operating Expenses	382.28	434.47	514.26	333.82	200.69
Operating Income	332.14	-342.28	-514.26	-324.16	-179.34
Interest Expense	-22.16	-23.39	-16.82	-18.69	-17.84
Interest & Investment Income	-	7.78	4.47	4.17	7.06
Currency Exchange Gain (Loss)	-	3.89	-0.43	14.46	-2.72
Other Non Operating Income (Expenses)	-	-	-	-0.06	-240.18
EBT Excluding Unusual Items	309.98	-354	-527.04	-324.28	-433.02
Gain (Loss) on Sale of Investments	-	4.24	5.7	11.9	6.48
Asset Writedown	-2.61	-	-	-	-
Pretax Income	307.37	-349.76	-521.33	-312.38	-426.54
Income Tax Expense	-0.07	-0.07	-0.07	-0.07	-0.07
Earnings From Continuing Operations	307.44	-349.69	-521.26	-312.31	-426.47
Minority Interest in Earnings	-	14.11	13.51	14.12	15.43
Net Income	307.44	-335.57	-507.75	-298.19	-411.04
Preferred Dividends & Other Adjustments	-	-	-	-	-112.77
Net Income to Common	307.44	-335.57	-507.75	-298.19	-298.27
Shares Outstanding (Basic)	218	219	206	178	116
Shares Outstanding (Diluted)	218	219	206	178	116
Shares Change (YoY)	-0.64%	6.70%	15.67%	52.95%	-
EPS (Basic)	1.41	-1.53	-2.47	-1.68	-2.57
EPS (Diluted)	1.41	-1.53	-2.47	-1.68	-2.57
Free Cash Flow	399.85	-187.31	-308.56	-245.33	-180.55
Free Cash Flow Per Share	1.83	-0.85	-1.50	-1.38	-1.55
Gross Margin	88.53%	58.06%	-	100.00%	100.00%
Operating Margin	41.16%	-215.55%	-	-3354.95%	-840.05%
Profit Margin	38.10%	-211.33%	-	-3086.22%	-1397.13%
Free Cash Flow Margin	49.55%	-117.96%	-	-2539.08%	-845.71%
EBITDA	362.6	-311.81	-484.13	-295.51	-155.65
EBITDA Margin	44.93%	-196.36%	-	-	-
D&A For EBITDA	30.46	30.46	30.13	28.65	23.7
EBIT	332.14	-342.28	-514.26	-324.16	-179.34
EBIT Margin	41.16%	-215.55%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.